Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...

The global needles market is projected to grow from USD 8.1 billion in 2024 to USD 14.7 billion by 2035, at a CAGR of 6.1%.

Semaglutide is already available in Ireland through diabetes medication Ozempic. However, its producer Novo Nordisk uses the ...

One of the losers of today's trading session was Novo Nordisk A/S ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 ...

You should dispose of GLP-1 pens in FDA-approved sharps disposal ... Drug manufacturer Novo Nordisk offers a free sharps container for those using Wegovy. The container comes with return shipping ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

An experimental obesity drug from Novo Nordisk resulted in 15.7% weight loss after 68 weeks of treatment — falling short of the company's expectations of 25% weight loss. The subcutaneous ...

Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy.

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...